Related Experiment Video

Updated: Apr 17, 2026

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

1.3K

[Pneumocystis jirovecii infection in non-HIV patients : diagnosis, treatment and prophylaxis]

Romain Gaillard1, Rezai Hassan Kalantari1

  • 1Service d'Oncologie, CHR Verviers, Belgique.

Revue Medicale De Liege
|April 16, 2026
PubMed

Insights

Pneumocystis pneumonia (PPJ) is a severe fungal infection in immunocompromised patients. Early diagnosis and treatment with trimethoprim-sulfamethoxazole are crucial for better outcomes in non-HIV individuals.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Immunocompromised Hosts

Background:

  • Pneumocystis jirovecii causes Pneumocystis pneumonia (PPJ), a life-threatening opportunistic infection.
  • PPJ incidence is rising due to increased immunosuppressive therapy use.
  • Non-HIV immunocompromised individuals, including those with malignancies or transplants, are at risk.

Purpose of the Study:

  • To review the epidemiology, clinical presentation, and treatment of PPJ in non-HIV patients.
  • To highlight the differences in PPJ characteristics between HIV and non-HIV patients.
  • To emphasize the importance of early diagnosis and treatment in this population.

Main Methods:

  • Literature review focusing on non-HIV patients with PPJ.
  • Analysis of diagnostic methods, primarily pathogen detection in pulmonary secretions.
  • Evaluation of treatment outcomes, with a focus on trimethoprim-sulfamethoxazole (TMP-SMX).

Main Results:

  • PPJ presents a significant morbidity and mortality rate (35-50%) in non-HIV patients.
  • Delayed diagnosis and treatment lead to poorer prognoses, with mortality reaching 90%.
  • Trimethoprim-sulfamethoxazole (TMP-SMX) is the primary treatment of choice.

Conclusions:

  • PPJ in non-HIV immunocompromised individuals requires specific clinical and therapeutic considerations.
  • Prompt diagnosis and appropriate TMP-SMX treatment are essential for improving patient survival.
  • Understanding the distinct features of PPJ in non-HIV patients is critical for effective management.
Keywords:
Pneumocystis jiroveciiPneumoniaPreventionTrimethoprim-sulfametoxazolenon-HIV

More Related Videos

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients07:25

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients

Published on: July 16, 2020

3.7K

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
4.1K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.4K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
4.4K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.3K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.4K